Eli Lilly Cuts Q4 Forecast Amid Weak Sales but Sees Bright 2025 with $61B Revenue Potential
Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly ( NYSE:LLY) revised its fourth-quarter revenue projection downward. Now estimating Q4 revenue at $13.5 billion, the company's projection falls short of analyst predictions of $13.96 billion.
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.
The London Metal Exchange is in its final stages to approve Hong Kong as the main warehousing network for its metals.
Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
The Indianapolis, Indiana-based company is set to release its Q4 earnings on Tuesday, Feb. 4. Ahead of the event, analysts expect Eli Lilly to report a profit of $5.43 per share, up 118.1% from ...
Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback